Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ: AMLX )

2.265 +0.005 (+0.22%)
Streaming Delayed Price Updated: 3:32 PM EDT, Aug 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Amylyx Pharmaceuticals Completes Negotiation Process and Signs Letter of Intent with the pCPA for ALBRIOZA™ for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Better Growth Stock: Amylyx Pharmaceuticals or Viking Therapeutics?
Which of these red-hot biotech stocks is the better buy right now? 
Via The Motley Fool
Amylyx Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
7 Analysts Have This to Say About Amylyx Pharma
Via Benzinga
What 7 Analyst Ratings Have To Say About Amylyx Pharma
Via Benzinga
Analyst Expectations for Amylyx Pharma's Future
Via Benzinga
Amylyx Pharma Earnings Preview
Via Benzinga
Analyst Ratings for Amylyx Pharma
Via Benzinga
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run
Shares surged into and out of the company's R&D Day, which included a surprise. 
Via Investor's Business Daily
Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Turns Profitable On Successful Drug Launch
Amylyx Pharmaceuticals is the rare young biotech that's profitable. The company earned $0.02 a share in Q1, and analysts expect profitability to grow. 
Via MarketBeat
2 Supercharged Growth Stocks to Buy Right Now
These two biopharma stocks might be poised for a major breakout. 
Via The Motley Fool
Expert Ratings for Amylyx Pharma
Via Benzinga
Looking Into Amylyx Pharmaceuticals's Return On Capital Employed
Via Benzinga
Analyst Expectations for Amylyx Pharma's Future
Via Benzinga
Why Amylyx Pharmaceuticals Stock Is Bolting Higher Today
The biopharma's new ALS drug is exceeding projections on the sales front. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
US Stock Futures Signal Strong Finish To Wobbly Week — But Analyst Still Sees Recession Risk On Horizon
Via Benzinga
Amylyx Blows Past Sales Expectations, Reports Unexpected Profit — Shares Rocket
The company was expected to post another loss, but instead came in with a gain of 2 cents per share. 
Via Investor's Business Daily
Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
3 Biotechs That Might Get Bought Out in 2023
Biotech is expected to be a hotbed of mergers and acquisitions this year. 
Via The Motley Fool
Amylyx Pharmaceuticals Appoints Masako Nakamura to General Manager and Head of International Markets - Asia Pacific and Latin America
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals - An Emerging Leader In ALS
Amylyx has sold off from its earnings report on March 13th. What has been driving this move and what does it mean for the long term prospects of Amylyx? 
Via Talk Markets
Amylyx Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
7 Biotech Stocks to Buy for 100% Returns
If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2023
Via Benzinga
Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review
A market rally is underway, but bank stocks kept tumbling. 
Via Investor's Business Daily
Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Ainos, Inc. (NASDAQ: AIMD) shares jumped 69.3% to $1.27 after the company announced it signed a Memorandum of Understanding with Merdury Biopharmaceutical to jointly explore and develop a... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.